Advances in carbohydrate-based nanoparticles for targeted therapy of inflammatory bowel diseases: A review

• Published in: International journal of biological macromolecules 2024-11, Vol.281 (Pt 4), p.136392, Article 136392
• Main Authors: Liang, Wenjing, Zhang, Wen, Tian, Jiayi, Zhang, Xinping, Lv, Xinyi, Qu, Ao, Chen, Jinyu, Wu, Zijian
• Format: Article
• Language: English
• Subjects: Administration, Oral; Animals; Carbohydrate; Carbohydrates - chemistry; Drug Carriers - chemistry; Drug Delivery Systems - methods; Humans; Inflammatory bowel disease; Inflammatory Bowel Diseases - drug therapy; Nanoparticles; Nanoparticles - chemistry; Oral administration; Targeted delivery system
• ISSN: 0141-8130; 1879-0003; 1879-0003
• DOI: 10.1016/j.ijbiomac.2024.136392

The incidence of inflammatory bowel disease (IBD), a chronic gastrointestinal disorder, is rapidly increasing worldwide. Unfortunately, the current therapies for IBD are often hindered by premature drug release and undesirable side effects. With the advancement of nanotechnology, the innovative targeted nanotherapeutics are explored to ensure the accurate delivery of drugs to specific sites in the colon, thereby reducing side effects and improving the efficacy of oral administration. The emphasis of this review is to summarize the potential pathogenesis of IBD and highlight recent breakthroughs in carbohydrate-based nanoparticles for IBD treatment, including their construction, release mechanism, potential targeting ability, and their therapeutic efficacy. Specifically, we summarize the latest knowledge regarding environmental-responsive nano-systems and active targeted nanoparticles. The environmental-responsive drug delivery systems crafted with carbohydrates or other biological macromolecules like chitosan and sodium alginate, exhibit a remarkable capacity to enhance the accumulation of therapeutic drugs in the inflamed regions of the digestive tract. Active targeting strategies improve the specificity and accuracy of oral drug delivery to the colon by modifying carbohydrates such as hyaluronic acid and mannose onto nanocarriers. Finally, we discuss the challenges and provide insight into the future perspectives of colon-targeted delivery systems for IBD treatment.